N-(2-hydroxypropyl)methacrylamide co-polymer-doxorubicin conjugate
RN in first source; PK1 (FCE-28068) is an N-(2-hydroxypropyl) methacrylamide (HPMA) co-polymer-doxorubicin conjugate, attached by a peptide linker; in phase II trials for breast, non-small-cell lung and colon cancers (6/2003)
Also Known As:
FCE-28068; FCE28068; HPMA-co-polymer-doxorubicin conjugate; PK1 compound
Networked: 4
relevant articles (0 outcomes,
4 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Duncan, Ruth:
2 articles
(06/2009 - 01/2007)
|
2. | Bissett, Donald:
1 article
(06/2009)
|
3. | Blackie, Robert:
1 article
(06/2009)
|
4. | Boivin, Christopher:
1 article
(06/2009)
|
5. | Burtles, Sally:
1 article
(06/2009)
|
6. | Calvert, Hilary:
1 article
(06/2009)
|
7. | Cassidy, James:
1 article
(06/2009)
|
8. | Ferry, David R:
1 article
(06/2009)
|
9. | Hesslewood, Stuart:
1 article
(06/2009)
|
10. | Jodrell, Duncan:
1 article
(06/2009)
|
Related Diseases
Related Drugs and Biologics
Related Therapies and Procedures